Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 2/20 | 0.52 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.52 |
| ▸ | GLA | P06280 | 1/20 | 0.52 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.50 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.50 |
| ▸ | PPARG | P37231 | 8/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 2/20 | 0.44 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.43 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2808920 | 0.85 | PPARG (0.56) | ALDH1A1PPARGSMN1; SMN2PPARAOPRK1 | |
| SCHEMBL2806787 | 0.85 | PPARG (0.66) | LMNAALDH1A1GLACYP1A2MAPT | |
| SCHEMBL2807718 | 0.75 | PPARG (0.78) | LMNAALDH1A1GLACYP1A2MAPT | |
| SCHEMBL2804812 | 0.74 | PPARG (0.69) | PPARGPPARA | |
| SCHEMBL2806027 | 0.73 | PPARG (0.84) | ALDH1A1MAPTPPARGPPARA | |
| SCHEMBL2811651 | 0.73 | PPARG (0.84) | ALDH1A1MAPTPPARGPPARA | |
| SCHEMBL2809038 | 0.73 | PPARG (0.84) | ALDH1A1MAPTPPARGPPARA | |
| SCHEMBL2807182 | 0.73 | PPARG (0.55) | LMNAALDH1A1MAPTPPARGSMN1; SMN2 | |
| SCHEMBL14176249 | 0.72 | PPARA (0.56) | LMNAALDH1A1CYP1A2CYP2C19PPARG | |
| SCHEMBL2804981 | 0.72 | OPRK1 (0.51) | ALDH1A1CYP1A2MAPTPPARGPPARA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-8513233-B2 | Pyrimidinyl-propionic acid derivatives and their use as PPAR agonists | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2013-08-20 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHENYANG SUNSHINE PHARMACEUTICAL COMPANY LIMITED (CN) | 2010-09-23 | — | — | US | disclosed |
| WO-2009046606-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | SHANGHAI INSTITUTE OF MATERIA MEDICA, CAS (CN) | 2009-04-16 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100240636-A1 | PYRIMIDINYL-PROPIONIC ACID DERIVATIVES AND THEIR USE AS PPAR AGONISTS | PPARA, PPARD, PPARG | LMNA 2582/4885ALDH1A1 838/4885GLA 3585/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.